Riskpilot← Back to searchSign inGet full accessPharma IT ApS
APSActiveCVR 37320595Skelbækgade 2, 6. tvComputer consultancy and computer facilities management activities · NACE 6220Est. 2015117 employeeswww.pharmait.dk
Revenue 2024
DKK 163,3M
+9% vs 2023
EBITDA margin
18.8%
+56% vs 2023
Equity ratio
53.6%
Financial strength
Net profit 2024
DKK 21,4M
+61% vs 2023
| Revenue | DKK 163,3M | +9% |
| EBITDA | DKK 30,6M | +56% |
| Net profit | DKK 21,4M | +61% |
| Total assets | DKK 95,4M | +30% |
| Equity | DKK 51,1M | +72% |
| Employees | 117 | — |
Legal name
Pharma IT ApS
CVR number
37320595
Legal form
Anpartsselskab
NACE code
6220 · Computer consultancy and computer facilities management activities
Founded
21. december 2015
Share capital
DKK 100.000
Employees
117 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at drive virksomhed med Konsulentbistand vedrørende informationsteknologi og hermed forbundet virksomhed.
Address
Skelbækgade 2, 6. tv
Phone
+4524342655
Email
info@pharmait.dk
Website
www.pharmait.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.000 | 12.509 | 25.178 | 40.473 | 80.389 | 83.977 | 138.610 | 149.905 | 163.257 |
| Staff expenses | -3.856 | -11.542 | -22.035 | -35.204 | -61.918 | -74.987 | -117.714 | -130.087 | -132.642 |
| EBITDA | 1.097 | 967 | 3.143 | 5.269 | 18.471 | 7.490 | 20.745 | 19.685 | 30.615 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -146 | -1.621 | -2.209 | -2.664 |
| EBIT | 1.097 | 967 | 3.143 | 5.269 | 18.471 | 7.343 | 19.125 | 17.476 | 27.951 |
| Net financials | -1 | -10 | -50 | -83 | -296 | -200 | -937 | -319 | -381 |
| Profit before tax | 1.096 | 957 | 3.093 | 5.186 | 18.175 | 7.143 | 18.188 | 17.157 | 27.571 |
| Tax | 242 | 221 | 700 | 1.171 | 4.053 | 1.948 | 4.086 | 3.855 | 6.133 |
| Net profit | 854 | 735 | 2.393 | 4.015 | 14.122 | 5.195 | 14.102 | 13.302 | 21.438 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.716 | 8.774 | 15.455 | 32.046 | 42.559 | 37.485 | 52.959 | 73.279 | 95.397 |
| Equity | 954 | 1.689 | 2.743 | 5.392 | 14.287 | 8.343 | 16.376 | 29.678 | 51.116 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.763 | 7.085 | 12.712 | 26.655 | 28.272 | 28.529 | 35.973 | 41.955 | 43.202 |
| Total debt | 3.763 | 7.085 | 12.712 | 26.655 | 28.272 | 28.529 | 35.973 | 41.955 | 43.202 |
EBITDA margin
18.8%
This company
15.8%
Market median
+19% vs market
20162024
Equity ratio
53.6%
This company
38.2%
Market median
+40% vs market
20162024
Return on equity
41.9%
This company
18.4%
Market median
+128% vs market
20162024
Net profit margin
13.1%
This company
8.1%
Market median
+62% vs market
20162024
Asset turnover
1.71×
This company
1.12×
Market median
+53% vs market
20162024
Debt / equity
0.87×
This company
0.62×
Market median
+40% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-12-21 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PI Management | Management | 2020 | — | — |
JJ Management | Management | 2023 | — | — |
BS Management | Management | 2023 | — | — |
SW Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ProductLife ApS | Company | 100.0% | 100.0% | 2022 |
| Individual | 5.0% | 5.0% | 2018 | |
| Individual | 5.0% | 5.0% | 2016 | |
Charlotte Bech Fribert Holding ApS | Company | 20.0% | 20.0% | 2019 |
H.Billeschou Holding ApS | Company | 5.0% | 5.0% | 2016 |
JaJR Holding ApS | Company | 33.3% | 33.3% | 2019 |
ProductLife Group ApS | Company | 50.0% | 50.0% | 2022 |
SqWi Holding ApS | Company | 33.3% | 33.3% | 2019 |
Pharma IT ApS | Company | 5.0% | 5.0% | 2018 |
| Individual | 5.0% | 5.0% | 2020 | |
PEI Holding ApS | Company | 10.0% | 10.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ProductLife Group ApS
Pharma IT ApS Board members of Pharma IT ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter-Emil Iversen | Management | 0 companies |
| Jakob Juul Rasmussen | Management | 0 companies |
| Birgitte Sloth | Management | 0 companies |
| Søren Winkel | Chief Executive Officer | 0 companies |
| Xavier Duburq | Chairman | 0 companies |
| Massimo Cunico | Chairman | 0 companies |